TNGX - Tango Therapeutics Inc
IEX Last Trade
11.81
0.690 5.843%
Share volume: 893,316
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$11.12
0.69
6.21%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-10 | 2022-11-10 | 2023-03-27 | 2023-05-09 | 2023-08-07 | 2023-11-08 | 2024-03-18 | 2024-05-08 | |
| Assets | |||||||||
| Total Assets | 448.399 M | 464.156 M | 436.470 M | 403.773 M | 379.328 M | 428.189 M | 402.567 M | 406.222 M | |
| Current Assets | 436.085 M | 401.674 M | 375.272 M | 343.000 M | 320.543 M | 370.891 M | 346.538 M | 352.036 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 17.162 M | 5.814 M | 6.572 M | 9.361 M | 9.035 M | 10.155 M | 8.797 M | 8.437 M | |
| Short Term Investments | 17.162 M | 5.814 M | 6.572 M | 9.361 M | 9.035 M | 10.155 M | 8.797 M | 8.437 M | |
| Total Receivables | 2.000 M | 2.000 M | 2.000 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 416.356 M | 393.293 M | 366.133 M | 333.639 M | 310.652 M | 359.880 M | 336.885 M | 343.599 M | |
| Total Non-current Assets | 12.314 M | 62.482 M | 61.198 M | 60.773 M | 58.785 M | 57.298 M | 56.029 M | 54.186 M | |
| Property Plant Equipment | 8.359 M | 11.296 M | 10.884 M | 11.106 M | 10.881 M | 10.261 M | 9.908 M | 9.522 M | |
| Other Assets | 532.000 K | 47.763 M | 46.891 M | 46.244 M | 45.337 M | 44.470 M | 43.554 M | 42.097 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 448.399 M | 464.156 M | 436.470 M | 403.773 M | 379.328 M | 428.189 M | 402.567 M | 406.222 M | |
| Total liabilities | 149.695 M | 191.084 M | 186.994 M | 176.509 M | 166.383 M | 151.594 M | 149.459 M | 141.770 M | |
| Total current liabilities | 44.684 M | 51.322 M | 55.545 M | 53.672 M | 53.633 M | 43.416 M | 45.938 M | 42.789 M | |
| Accounts Payable | 1.693 M | 6.314 M | 4.453 M | 6.296 M | 4.793 M | 2.837 M | 2.785 M | 3.898 M | |
| Other liabilities | 105.011 M | 99.815 M | 92.088 M | 84.102 M | 74.668 M | 70.712 M | 66.683 M | 62.812 M | |
| Current long term debt | 629.000 K | 781.000 K | 1.770 M | 2.638 M | 1.807 M | 2.040 M | 2.082 M | 2.066 M | |
| Long term debt | 0.000 | 39.947 M | 39.361 M | 38.735 M | 38.082 M | 37.466 M | 36.838 M | 36.169 M | |
| Other liabilities | 105.011 M | 99.815 M | 92.088 M | 84.102 M | 74.668 M | 70.712 M | 66.683 M | 62.812 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 298.704 M | 273.072 M | 249.476 M | 227.264 M | 212.945 M | 276.595 M | 253.108 M | 264.452 M | |
| Common stock | 87.840 M | 87.892 M | 87.877 M | 88.194 M | 88.355 M | 97.033 M | 104.708 M | 108.171 M | |
| Retained earnings | -211.402 M | -240.452 M | -269.512 M | -297.520 M | -318.230 M | -340.493 M | -371.256 M | -409.170 M |